1155 Thromboembolic Risk After Tranexamic Acid Use in High-Risk Adult Spinal Deformity Patients

View at publisher Summarise with VIRAT
Authors: Jeffrey Paul Mullin, Mohamed A. Soliman, Justin S. Smith, Michael Kelly, Thomas J. Buell, Bassel Georges Diebo, Justin Kemp Scheer, Breton G. Line, Virginie Lafage, Renaud Lafage, Eric O. Klineberg, Han Jo Kim
+17 more Peter G. Passias, Jeffrey Lynn Gum, Khaled M. Kebaish, Robert K. Eastlack, Alan H. Daniels, Alex Soroceanu, Gregory M. Mundis, Richard A. Hostin, Themistocles Stavros Protopsaltis, D. Kojo Hamilton, Munish C. Gupta, Stephen Lewis, Frank Schwab, Christopher I. Shaffrey, Shay R. Bess, Christopher Pearson Ames, Douglas C. Burton
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Managing blood loss in complex spinal deformity surgery is critical, and tranexamic acid (TXA) has shown effectiveness in minimizing intraoperative bleeding. However, its safety profile in patients with a history of thromboembolic conditions remains unclear, raising concerns about its use in high-risk populations. METHODS: A multicenter retrospective analysis was conducted on adult patients who underwent complex spinal deformity correction and received TXA across 21 North American institutions between August 2018 and October 2022. Patients were categorized as high-risk if they had a prior history of thromboembolic events, including DVT, PE, MI, stroke, peripheral vascular disease, or cancer. Complication rates were tracked for 90 days postoperatively. Univariate and multivariate analyses were performed to evaluate associations between risk status and thromboembolic events. RESULTS: Of 411 patients who received intraoperative TXA, 130 (31.6%) were considered high-risk. No significant difference was found in overall thromboembolic complications between high-risk and low-risk patients (8.5% vs 2.8%, p = 0.45). Rates of DVT (1.5% vs 1.4%, p = 0.98), PE (2.3% vs 1.8%, p = 0.71), MI (1.5% vs 0%, p = 0.19), and stroke (0.8% vs 1.1%, p > 0.99) were comparable between groups. Multivariate analysis confirmed that high-risk status did not significantly predict thromboembolic events. CONCLUSIONS: In this multicenter cohort, intravenous TXA use during spinal deformity surgery was not associated with increased thromboembolic risk in patients with preexisting conditions. These findings support the cautious use of TXA even in high-risk populations, though continued surveillance is warranted.

Fields of Study & Subjects

Blood transfusion and management Venous Thromboembolism Diagnosis and Management Spinal Hematomas and Complications

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
222–222
Publication date
26 March 2026
Language
EN